Department of Thoracic Surgery, Peking University People's Hospital, China.
Department of Thoracic Surgery, Peking University People's Hospital, China.
Lung Cancer. 2019 Mar;129:98-106. doi: 10.1016/j.lungcan.2018.11.012. Epub 2018 Nov 13.
Selected non-small cell lung cancer (NSCLC) patients with extrathoracic metastases might benefit from surgical intervention; however, the evidence is limited. We investigated the benefit of surgery in these patients regarding the extent of the metastatic disease.
Patients with extrathoracic metastatic NSCLC were identified in the US National Cancer Institute Surveillance, Epidemiology, and End Results database (2010-2015). Survival was compared before and after matching. Multivariate Cox regression models were built to identify factors associated with survival and to adjust for covariates in subgroup analysis.
Of the 39,655 patients, 1206 underwent primary tumor resection, and 630 patients were identified 1:1 in surgical and nonsurgical groups after matching. In the entire cohort, patients who underwent surgery had significant prolonged overall survival (OS) in both unmatched (median survival time, [MST]: 14 vs. 6 months, p < 0.001) and matched (MST: 11 vs. 7 months, p < 0.001) cohorts. In the highly selected surgery-recommended cohort, surgical group still had a significantly longer OS (MST: 14 vs. 6 months, p < 0.001). Multivariate regression showed that surgery was independently associated with improved OS and lung cancer-specific mortality (LCSM) (OS: hazard ratio [HR]: 0.60, 95% confidence interval [CI]: 0.56-0.64, p < 0.001; LCSM: subhazard ratio [SHR]: 0.61, 95% CI: 0.57-0.66, p < 0.001). Subgroup analysis showed that surgery was an independent favorable predictor to survival in all cohorts except patients with N3 disease, and patients with single-organ metastasis were associated with the most prominent survival benefit from surgery.
Primary tumor resection was associated with improved survival in extrathoracic metastatic NSCLC patients, particularly for those with single-organ metastasis.
患有胸外转移的非小细胞肺癌(NSCLC)患者可能受益于手术干预;然而,证据有限。我们研究了这些患者的转移疾病程度与手术获益的关系。
在美国国家癌症研究所监测、流行病学和结果数据库(2010-2015 年)中确定患有胸外转移性 NSCLC 的患者。生存情况在匹配前后进行比较。建立多变量 Cox 回归模型以确定与生存相关的因素,并在亚组分析中调整协变量。
在 39655 名患者中,有 1206 名患者接受了原发肿瘤切除术,并且在匹配后,630 名患者被分配到手术组和非手术组。在整个队列中,接受手术的患者在未匹配(中位生存时间 [MST]:14 个月比 6 个月,p<0.001)和匹配(MST:11 个月比 7 个月,p<0.001)队列中均有显著延长的总生存期(OS)。在高度推荐手术的队列中,手术组的 OS 仍然显著延长(MST:14 个月比 6 个月,p<0.001)。多变量回归显示,手术与改善 OS 和肺癌特异性死亡率(LCSM)独立相关(OS:风险比 [HR]:0.60,95%置信区间 [CI]:0.56-0.64,p<0.001;LCSM:亚风险比 [SHR]:0.61,95% CI:0.57-0.66,p<0.001)。亚组分析表明,手术是所有队列中 OS 的独立有利预测因素,除了 N3 疾病患者和单一器官转移患者外,后者与手术带来的最显著生存获益相关。
原发肿瘤切除术与胸外转移性 NSCLC 患者的生存改善相关,尤其是对于单一器官转移的患者。